Steven H. J. Hageman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Steven H. J. Hageman has a total of 520 co-authors. Here are the top co-authors by number of shared publications:
- Jannick A. N. Dorresteijn
University Medical Center Utrecht
22 shared publications - Frank L. J. Visseren
University Medical Center Utrecht
20 shared publications - Emanuele Di Angelantonio
Human Technopole, Milan, Italy
14 shared publications - Stephen Kaptoge
British Heart Foundation Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge , Cambridge
11 shared publications - Lisa Pennells
British Heart Foundation Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge , Papworth Road, Cambridge Biomedical Campus, Cambridge CB2 0BB
9 shared publications John William McEvoy
7 shared publications
Latest Publications
- Open Access
Improving cardiovascular population risk in primary care: protocol for the PROSPERA cluster-randomised controlled trial of a complex multilevel intervention
Introduction The growing burden of cardiovascular disease (CVD) threatens the sustainability of our healthcare systems. In the Netherlands, two-thirds of CVD-related healthcare is delivered in primary care practices. Given the increasing staffing shortages and the substantial heterogeneity of the population of primary care patients at increased risk of CVD, cardiovascular risk management strategies should be better tailored to individual patients’ needs and risk profiles. Therefore, we developed the PROSPERA programme, a population-level risk-based approach aimed at improving cardiovascular risk management in primary care. Methods and analysis The PROSPERA study is a pragmatic 1:1 cluster randomised controlled trial in 22 primary care practices in the greater Leiden and The Hague region in the Netherlands, investigating real-world effectiveness of usual care plus the PROSPERA programme with usual care alone. The PROSPERA programme consists of (1) a population-level risk stratification overview to anticipate care needs (empanelment), (2) training for healthcare professionals in cardiovascular risk communication, (3) a lifestyle questionnaire completed by patients before consultation (Lifestylecheck) and (4) a clinical decision support tool (U-Prevent). The programme aims to support a more targeted use of available resources by identifying patients at higher risk and tailoring preventive efforts to those who may benefit most, thereby potentially improving the efficiency and effectiveness of care. Patients between 40 and 90 years of age enrolled in integrated care programmes (programmes developed to ensure a continuum of care for patients with chronic conditions) for increased cardiovascular risk are included. The primary outcome is defined as the proportion of the participants with successful achievement of all protocol-defined cardiovascular preventive treatment goals at 18 months of follow-up. Secondary outcomes include implementation outcomes (penetration and fidelity), healthcare professionals’ satisfaction on usability of the PROSPERA programme, patient experience with shared decision-making and decisional conflict when making a healthcare decision and outcomes on cost-effectiveness. Ethics and dissemination Consent for the use of routine healthcare data are obtained through an opt-out procedure for participating practices. Digital informed consent will be obtained for the study questionnaires for patients and healthcare professionals. Main findings on effectivity, efficacy and implementation will be disseminated via peer-reviewed journals and via (inter)national conferences. Trial registration number NCT06593704.
Open AccessImproving cardiovascular population risk in primary care: protocol for the PROSPERA cluster-randomised controlled trial of a complex multilevel intervention
Introduction The growing burden of cardiovascular disease (CVD) threatens the sustainability of our healthcare systems. In the Netherlands, two-thirds of CVD-related healthcare is delivered in primary care practices. Given the increasing staffing shortages and the substantial heterogeneity of the population of primary care patients at increased risk of CVD, cardiovascular risk management strategies should be better tailored to individual patients’ needs and risk profiles. Therefore, we developed the PROSPERA programme, a population-level risk-based approach aimed at improving cardiovascular risk management in primary care. Methods and analysis The PROSPERA study is a pragmatic 1:1 cluster randomised controlled trial in 22 primary care practices in the greater Leiden and The Hague region in the Netherlands, investigating real-world effectiveness of usual care plus the PROSPERA programme with usual care alone. The PROSPERA programme consists of (1) a population-level risk stratification overview to anticipate care needs (empanelment), (2) training for healthcare professionals in cardiovascular risk communication, (3) a lifestyle questionnaire completed by patients before consultation (Lifestylecheck) and (4) a clinical decision support tool (U-Prevent). The programme aims to support a more targeted use of available resources by identifying patients at higher risk and tailoring preventive efforts to those who may benefit most, thereby potentially improving the efficiency and effectiveness of care. Patients between 40 and 90 years of age enrolled in integrated care programmes (programmes developed to ensure a continuum of care for patients with chronic conditions) for increased cardiovascular risk are included. The primary outcome is defined as the proportion of the participants with successful achievement of all protocol-defined cardiovascular preventive treatment goals at 18 months of follow-up. Secondary outcomes include implementation outcomes (penetration and fidelity), healthcare professionals’ satisfaction on usability of the PROSPERA programme, patient experience with shared decision-making and decisional conflict when making a healthcare decision and outcomes on cost-effectiveness. Ethics and dissemination Consent for the use of routine healthcare data are obtained through an opt-out procedure for participating practices. Digital informed consent will be obtained for the study questionnaires for patients and healthcare professionals. Main findings on effectivity, efficacy and implementation will be disseminated via peer-reviewed journals and via (inter)national conferences. Trial registration number NCT06593704.
- 29 August 2026
- Published by Oxford University Press (OUP) in European Heart Journal
Development and external validation of the SCORE2 models in Latin America and the Caribbean (SCORE2-LAC) to estimate 10-year cardiovascular disease risk
Background and Aims: Despite the high burden of cardiovascular disease (CVD) in Latin America and the Caribbean (LAC), risk prediction models adapted for use in LAC populations remain limited. The aim of this study was to recalibrate the Systematic COronary Risk Evaluation 2 (SCORE2) risk models for estimating 10-year CVD risk in individuals without prior CVD or diabetes mellitus in LAC, resulting in the SCORE2 Latin America and the Caribbean (SCORE2-LAC) models. Methods: Sex-specific, competing risk-adjusted SCORE2 models were recalibrated to contemporary CVD incidence across four risk regions, defined by country-level age- and sex-standardized CVD mortality rates, using region-specific risk factor distributions. Cardiovascular disease incidence was estimated from CVD mortality data and ratios of the total first-to-fatal CVD events, derived from 40 237 152 individuals (1 261 329 CVD events). External validation included 132 512 individuals without prior CVD or diabetes from 11 cohorts across seven countries (3938 CVD events). Discrimination was assessed using Harrell’s C-index. Results: In the external validation datasets, the pooled C-index of SCORE2-LAC was .740 [95% confidence interval (CI) .716–.763], with cohort-specific C-indices ranging from .674 (95% CI .588–.761) to .789 (95% CI .747–.831). Estimated CVD risk varied several-fold across the four LAC risk regions. For a 50-year-old non-smoker with a systolic blood pressure of 140 mmHg, total cholesterol of 213 mg/dL (5.5 mmol/L), and HDL cholesterol of 50 mg/dL (1.3 mmol/L), the predicted risk ranged from 3% in low-risk countries to 10% in very-high-risk countries for women, and from 4% to 10% for men. Conclusions: The SCORE2-LAC models provide region-specific contemporary estimates of 10-year CVD risk in apparently healthy individuals, enabling identification of individuals at high CVD risk across LAC.
- 29 August 2026
- Published by Oxford University Press (OUP) in European Heart Journal
Development and external validation of the SCORE2 models in Latin America and the Caribbean (SCORE2-LAC) to estimate 10-year cardiovascular disease risk
Background and Aims: Despite the high burden of cardiovascular disease (CVD) in Latin America and the Caribbean (LAC), risk prediction models adapted for use in LAC populations remain limited. The aim of this study was to recalibrate the Systematic COronary Risk Evaluation 2 (SCORE2) risk models for estimating 10-year CVD risk in individuals without prior CVD or diabetes mellitus in LAC, resulting in the SCORE2 Latin America and the Caribbean (SCORE2-LAC) models. Methods: Sex-specific, competing risk-adjusted SCORE2 models were recalibrated to contemporary CVD incidence across four risk regions, defined by country-level age- and sex-standardized CVD mortality rates, using region-specific risk factor distributions. Cardiovascular disease incidence was estimated from CVD mortality data and ratios of the total first-to-fatal CVD events, derived from 40 237 152 individuals (1 261 329 CVD events). External validation included 132 512 individuals without prior CVD or diabetes from 11 cohorts across seven countries (3938 CVD events). Discrimination was assessed using Harrell’s C-index. Results: In the external validation datasets, the pooled C-index of SCORE2-LAC was .740 [95% confidence interval (CI) .716–.763], with cohort-specific C-indices ranging from .674 (95% CI .588–.761) to .789 (95% CI .747–.831). Estimated CVD risk varied several-fold across the four LAC risk regions. For a 50-year-old non-smoker with a systolic blood pressure of 140 mmHg, total cholesterol of 213 mg/dL (5.5 mmol/L), and HDL cholesterol of 50 mg/dL (1.3 mmol/L), the predicted risk ranged from 3% in low-risk countries to 10% in very-high-risk countries for women, and from 4% to 10% for men. Conclusions: The SCORE2-LAC models provide region-specific contemporary estimates of 10-year CVD risk in apparently healthy individuals, enabling identification of individuals at high CVD risk across LAC.
- Open Access
Healthcare professionals’ perspectives on a multilevel cardiovascular risk management intervention (PROSPERA programme)
Background: Two-thirds of Dutch cardiovascular risk management (CVRM) for patients at risk of cardiovascular disease is delivered in primary care practices. While individual risk scores are increasingly used during consultation, a population-level structure for risk-based patient outreach is not currently available. We therefore developed the PROSPERA programme, a multilevel intervention comprising population-level risk stratification and individual-level support tools. Aim: To assess anticipated and experienced barriers and facilitators among healthcare professionals (HCPs) to inform implementation in primary care. Methods: We conducted four focus groups and six interviews with nine primary care HCPs to explore anticipated and experienced barriers and facilitators. Inductive codes were thematically analysed and assigned to corresponding domains of the Theoretical Domains Framework (TDF) and the related Capability, Opportunity, Motivation model of Behaviour. Results: Barriers and facilitators were identified in 11 TDF domains. Population-level barriers included altered professional roles and limitations in technological infrastructure. Individual-level barriers were limited skills in interpreting risk calculations and difficulty integrating tools into clinical routine. Facilitators were related to beliefs on the importance of providing proactive care (population level), the use of U-Prevent for risk communication (individual level) and positive patient responses to the Lifestylecheck questionnaire (individual level). Conclusion: Addressing barriers and facilitators identified at both the population and individual levels can support implementation of the PROSPERA programme. Opportunities exist in education and training of HCPs in risk communication, as well as support in restructuring the physical and digital environment.
Open AccessHealthcare professionals’ perspectives on a multilevel cardiovascular risk management intervention (PROSPERA programme)
Background: Two-thirds of Dutch cardiovascular risk management (CVRM) for patients at risk of cardiovascular disease is delivered in primary care practices. While individual risk scores are increasingly used during consultation, a population-level structure for risk-based patient outreach is not currently available. We therefore developed the PROSPERA programme, a multilevel intervention comprising population-level risk stratification and individual-level support tools. Aim: To assess anticipated and experienced barriers and facilitators among healthcare professionals (HCPs) to inform implementation in primary care. Methods: We conducted four focus groups and six interviews with nine primary care HCPs to explore anticipated and experienced barriers and facilitators. Inductive codes were thematically analysed and assigned to corresponding domains of the Theoretical Domains Framework (TDF) and the related Capability, Opportunity, Motivation model of Behaviour. Results: Barriers and facilitators were identified in 11 TDF domains. Population-level barriers included altered professional roles and limitations in technological infrastructure. Individual-level barriers were limited skills in interpreting risk calculations and difficulty integrating tools into clinical routine. Facilitators were related to beliefs on the importance of providing proactive care (population level), the use of U-Prevent for risk communication (individual level) and positive patient responses to the Lifestylecheck questionnaire (individual level). Conclusion: Addressing barriers and facilitators identified at both the population and individual levels can support implementation of the PROSPERA programme. Opportunities exist in education and training of HCPs in risk communication, as well as support in restructuring the physical and digital environment.
- Open Access
- 5 June 2026
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 47 (39) , 5840-5856
Predicting lifetime cardiovascular risk and benefits of preventive treatment in patients with established atherosclerotic cardiovascular disease: the SMART-REACH2 model
Background and Aims: The 2021 ESC guidelines on cardiovascular (CV) disease prevention recommend the SMART-REACH lifetime risk model to guide treatment decisions in patients with established atherosclerotic CV disease. The aim was to develop the SMART-REACH2 model for estimating lifetime risk of recurrent CV events and treatment benefits in patients with established atherosclerotic CV disease, with systematic recalibration to the four European and other global risk regions. Methods: SMART-REACH2 was derived in 8708 individuals aged 40–90 years with coronary, cerebrovascular, peripheral artery disease and/or abdominal aortic aneurysm from the UCC-SMART cohort. Sex-stratified, cause-specific Cox models for recurrent CV events and non-CV death were fitted using age as timescale and routinely available predictors. Recurrent CV events were defined as a composite of myocardial infarction, stroke, or CV death. Recalibration was based on representative cohorts per risk region. External validation was performed in 2 085 780 patients from 54 countries; model performance was assessed by calibration plots and Harrell's C-statistic. Results: In the derivation cohort, 2057 recurrent CV events occurred over a median follow-up of 8.5 years (25th–75th: 4.3–13.0). In external validation, 307 706 events occurred. The pooled C-statistic was 0.68 (95% confidence interval 0.66–0.69) and ranged from 0.66 (0.64–0.69) for European low-risk region up to 0.72 (0.66–0.78) for Latin America, with adequate calibration across risk regions. Performance was consistent across sexes and CV disease subtypes. Using SMART-REACH2, estimated potential gains in CV disease-free life expectancy for a 50-year-old example patient receiving intensified preventive treatment (15 mmHg systolic blood pressure and 1.0 mmol/L low-density lipoprotein cholesterol reduction) ranged from 2 years in the low-risk region to 4.4 years in the very-high-risk region. Conclusions: The updated SMART-REACH2 model accounts for geographical and sex-specific variations and allows estimation of short-term and lifetime risk of recurrent CV events and treatment benefits, facilitating shared decision-making as recommended by guidelines.
- 5 June 2026
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 47 (39) , 5840-5856
Open AccessPredicting lifetime cardiovascular risk and benefits of preventive treatment in patients with established atherosclerotic cardiovascular disease: the SMART-REACH2 model
Background and Aims: The 2021 ESC guidelines on cardiovascular (CV) disease prevention recommend the SMART-REACH lifetime risk model to guide treatment decisions in patients with established atherosclerotic CV disease. The aim was to develop the SMART-REACH2 model for estimating lifetime risk of recurrent CV events and treatment benefits in patients with established atherosclerotic CV disease, with systematic recalibration to the four European and other global risk regions. Methods: SMART-REACH2 was derived in 8708 individuals aged 40–90 years with coronary, cerebrovascular, peripheral artery disease and/or abdominal aortic aneurysm from the UCC-SMART cohort. Sex-stratified, cause-specific Cox models for recurrent CV events and non-CV death were fitted using age as timescale and routinely available predictors. Recurrent CV events were defined as a composite of myocardial infarction, stroke, or CV death. Recalibration was based on representative cohorts per risk region. External validation was performed in 2 085 780 patients from 54 countries; model performance was assessed by calibration plots and Harrell's C-statistic. Results: In the derivation cohort, 2057 recurrent CV events occurred over a median follow-up of 8.5 years (25th–75th: 4.3–13.0). In external validation, 307 706 events occurred. The pooled C-statistic was 0.68 (95% confidence interval 0.66–0.69) and ranged from 0.66 (0.64–0.69) for European low-risk region up to 0.72 (0.66–0.78) for Latin America, with adequate calibration across risk regions. Performance was consistent across sexes and CV disease subtypes. Using SMART-REACH2, estimated potential gains in CV disease-free life expectancy for a 50-year-old example patient receiving intensified preventive treatment (15 mmHg systolic blood pressure and 1.0 mmol/L low-density lipoprotein cholesterol reduction) ranged from 2 years in the low-risk region to 4.4 years in the very-high-risk region. Conclusions: The updated SMART-REACH2 model accounts for geographical and sex-specific variations and allows estimation of short-term and lifetime risk of recurrent CV events and treatment benefits, facilitating shared decision-making as recommended by guidelines.
- Open Access
- 1 June 2026
- Published by Oxford University Press (OUP) in European Heart Journal - Quality of Care and Clinical Outcomes
- Vol. 12 (7) , 1212-1222
Comparison of different long-term cardiovascular disease risk prediction horizons to guide preventive drug treatment in apparently healthy individuals
Aims: Guideline-recommended long-term cardiovascular disease (CVD) risk prediction models use varying time horizons. This study compared which risk horizon (risk until ages 80 or 95 years, or 30-year risk) most effectively guides preventive treatment in apparently healthy individuals. Methods and results: CVD risks for all horizon were estimated using the LIFE-CVD2 model in individuals aged 35–69 years without CVD or diabetes from the Dutch ELAN registry (2007–2024; n = 364 003) and the EPIC-InterAct subcohort (1992–1998; n = 8813). Individuals in the top risk decile were compared across time horizons. Simulating blood pressure- and lipid-lowering therapy, the impact of using either time horizon was assessed by the expected gain in CVD-free life years and lifetime CVD events prevented. Individuals identified by 30-year risk were predominantly older and largely overlapped with 10-year risk (46%). In contrast, risk until ages 80 and 95 years showed less overlap with 10-year risk (18% and 20%, respectively) and identified more young men in the highest risk decile. Treatment guided by risk until ages 80 and 95 years yielded a median gain of 2.6 [IQR 2.2–2.9] CVD-free life years per person treated, with prevention of 4434 and 4658 CVD events, respectively, compared with 1.8 [IQR 1.4–1.9] years and 4215 events for 30-year risk. A hybrid strategy combining 10-year risk with risk until age 80 years yielded a median gain of 2.5 [IQR 2.1–3.0] CVD-free life years. Conclusion: Long-term CVD risk estimation until age 80 years offers a pragmatic approach to identify younger high-risk individuals not captured by 10-year risk who may benefit from preventive treatment.
- 1 June 2026
- Published by Oxford University Press (OUP) in European Heart Journal - Quality of Care and Clinical Outcomes
- Vol. 12 (7) , 1212-1222
Open AccessComparison of different long-term cardiovascular disease risk prediction horizons to guide preventive drug treatment in apparently healthy individuals
Aims: Guideline-recommended long-term cardiovascular disease (CVD) risk prediction models use varying time horizons. This study compared which risk horizon (risk until ages 80 or 95 years, or 30-year risk) most effectively guides preventive treatment in apparently healthy individuals. Methods and results: CVD risks for all horizon were estimated using the LIFE-CVD2 model in individuals aged 35–69 years without CVD or diabetes from the Dutch ELAN registry (2007–2024; n = 364 003) and the EPIC-InterAct subcohort (1992–1998; n = 8813). Individuals in the top risk decile were compared across time horizons. Simulating blood pressure- and lipid-lowering therapy, the impact of using either time horizon was assessed by the expected gain in CVD-free life years and lifetime CVD events prevented. Individuals identified by 30-year risk were predominantly older and largely overlapped with 10-year risk (46%). In contrast, risk until ages 80 and 95 years showed less overlap with 10-year risk (18% and 20%, respectively) and identified more young men in the highest risk decile. Treatment guided by risk until ages 80 and 95 years yielded a median gain of 2.6 [IQR 2.2–2.9] CVD-free life years per person treated, with prevention of 4434 and 4658 CVD events, respectively, compared with 1.8 [IQR 1.4–1.9] years and 4215 events for 30-year risk. A hybrid strategy combining 10-year risk with risk until age 80 years yielded a median gain of 2.5 [IQR 2.1–3.0] CVD-free life years. Conclusion: Long-term CVD risk estimation until age 80 years offers a pragmatic approach to identify younger high-risk individuals not captured by 10-year risk who may benefit from preventive treatment.
- Open Access
- 11 March 2026
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 47 (34) , 4743-4757
Prediction of incident heart failure in established atherosclerotic cardiovascular disease: the SMART2-HF model
Background and Aims: Patients with established atherosclerotic cardiovascular disease (ASCVD) are at high risk of developing heart failure (HF). However, incident HF is not part of the risk assessment of current guideline-recommended models. The aim of this study was to develop and externally validate the SMART2-HF model for prediction of incident HF in patients with ASCVD. Methods: SMART2-HF was developed in 7698 individuals with established ASCVD (coronary, cerebrovascular, or peripheral artery disease, or abdominal aortic aneurysm) but without prior HF from the UCC-SMART cohort. Cox proportional hazards models including sex-predictor interactions and with age as the time scale were derived to estimate the 10-year and lifetime risk of incident HF (hospitalization for HF or HF-related death), accounting for competing non-HF mortality. Predictors, limited to routinely available clinical characteristics, were aligned with the SMART2 risk model for recurrent cardiovascular (CV) risk in the same population. External validation was performed in 240 741 patients with ASCVD from six data sources: the Clinical Practice Research Datalink, the HUNT3 study, the SWEDEHEART Registry, the ASCVD-Particles cohort, the Estonian Biobank and the international REACH Registry. Results: During a median follow-up of 11.2 years (interquartile range 6.1–16.4 years), 1031 incident HF events (13%) occurred in the UCC-SMART cohort. In the external validation data sources, a total of 24 885 incident HF events (10%) occurred. The pooled C-statistic was .696 (95% confidence interval .674–.717), with consistent performance in subgroups by sex and type of ASCVD. Predicted risks matched observed incidence in external validation. Conclusions: The SMART2-HF model enables the prediction of incident HF in patients with ASCVD. Aligned with the guideline-recommended SMART2 model for recurrent CV risk, SMART2-HF can be used as a complementary tool in this population.
- 11 March 2026
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 47 (34) , 4743-4757
Open AccessPrediction of incident heart failure in established atherosclerotic cardiovascular disease: the SMART2-HF model
Background and Aims: Patients with established atherosclerotic cardiovascular disease (ASCVD) are at high risk of developing heart failure (HF). However, incident HF is not part of the risk assessment of current guideline-recommended models. The aim of this study was to develop and externally validate the SMART2-HF model for prediction of incident HF in patients with ASCVD. Methods: SMART2-HF was developed in 7698 individuals with established ASCVD (coronary, cerebrovascular, or peripheral artery disease, or abdominal aortic aneurysm) but without prior HF from the UCC-SMART cohort. Cox proportional hazards models including sex-predictor interactions and with age as the time scale were derived to estimate the 10-year and lifetime risk of incident HF (hospitalization for HF or HF-related death), accounting for competing non-HF mortality. Predictors, limited to routinely available clinical characteristics, were aligned with the SMART2 risk model for recurrent cardiovascular (CV) risk in the same population. External validation was performed in 240 741 patients with ASCVD from six data sources: the Clinical Practice Research Datalink, the HUNT3 study, the SWEDEHEART Registry, the ASCVD-Particles cohort, the Estonian Biobank and the international REACH Registry. Results: During a median follow-up of 11.2 years (interquartile range 6.1–16.4 years), 1031 incident HF events (13%) occurred in the UCC-SMART cohort. In the external validation data sources, a total of 24 885 incident HF events (10%) occurred. The pooled C-statistic was .696 (95% confidence interval .674–.717), with consistent performance in subgroups by sex and type of ASCVD. Predicted risks matched observed incidence in external validation. Conclusions: The SMART2-HF model enables the prediction of incident HF in patients with ASCVD. Aligned with the guideline-recommended SMART2 model for recurrent CV risk, SMART2-HF can be used as a complementary tool in this population.
- Open Access
Improving cardiovascular population risk in primary care: protocol for the PROSPERA cluster-randomized controlled trial of a complex multilevel intervention
Introduction: The growing burden of cardiovascular disease (CVD) threatens the sustainability of our healthcare systems. In the Netherlands, two-thirds of CVD-related healthcare is delivered in primary care practices, primarily by practice nurses. Given the increasing staffing shortages and the substantial heterogeneity of the population of primary care patients at increased risk of CVD, cardiovascular risk management strategies should be better tailored to individual patients' needs and risk profiles. Therefore, we developed the PROSPERA program, aimed at the population of patients enrolled in integrated care programs for cardiovascular risk management in primary care. Methods and analysis: The PROSPERA study is a pragmatic 1:1 cluster randomized controlled trial in 22 primary care practices in the greater Leiden and the Hague region in The Netherlands, investigating real-world effectiveness of the PROSPERA program with care as usual. The PROSPERA program is a multilevel complex intervention, including a population-level risk stratification and three individual patient-level components: a healthcare professional training program in cardiovascular risk communication, a lifestyle questionnaire (Lifestylecheck), and a clinical decision support tool (U-Prevent). Patients between 40-90 years of age enrolled in integrated care programs for increased cardiovascular risk are included. The primary outcome is defined as successful achievement of all protocol-defined cardiovascular preventive treatment goals, measured as the difference between the proportion of patients who meet the outcome in the intervention versus the control group at 18 months. Secondary outcomes include implementation outcomes, healthcare professionals' satisfaction on usability of the PROSPERA program, patient experience with shared decision making and decisional conflict, and outcomes on cost-effectiveness. Ethics and dissemination: Consent for the use of routine healthcare data is obtained through an opt-out procedure for participating practices. Digital informed consent will be obtained for the study questionnaires for patients and healthcare professionals. Main findings on effectivity, efficacy and implementation will be disseminated via peer-reviewed journals and via (inter)national conferences. Trial registration number: NCT06593704
Open AccessImproving cardiovascular population risk in primary care: protocol for the PROSPERA cluster-randomized controlled trial of a complex multilevel intervention
Introduction: The growing burden of cardiovascular disease (CVD) threatens the sustainability of our healthcare systems. In the Netherlands, two-thirds of CVD-related healthcare is delivered in primary care practices, primarily by practice nurses. Given the increasing staffing shortages and the substantial heterogeneity of the population of primary care patients at increased risk of CVD, cardiovascular risk management strategies should be better tailored to individual patients' needs and risk profiles. Therefore, we developed the PROSPERA program, aimed at the population of patients enrolled in integrated care programs for cardiovascular risk management in primary care. Methods and analysis: The PROSPERA study is a pragmatic 1:1 cluster randomized controlled trial in 22 primary care practices in the greater Leiden and the Hague region in The Netherlands, investigating real-world effectiveness of the PROSPERA program with care as usual. The PROSPERA program is a multilevel complex intervention, including a population-level risk stratification and three individual patient-level components: a healthcare professional training program in cardiovascular risk communication, a lifestyle questionnaire (Lifestylecheck), and a clinical decision support tool (U-Prevent). Patients between 40-90 years of age enrolled in integrated care programs for increased cardiovascular risk are included. The primary outcome is defined as successful achievement of all protocol-defined cardiovascular preventive treatment goals, measured as the difference between the proportion of patients who meet the outcome in the intervention versus the control group at 18 months. Secondary outcomes include implementation outcomes, healthcare professionals' satisfaction on usability of the PROSPERA program, patient experience with shared decision making and decisional conflict, and outcomes on cost-effectiveness. Ethics and dissemination: Consent for the use of routine healthcare data is obtained through an opt-out procedure for participating practices. Digital informed consent will be obtained for the study questionnaires for patients and healthcare professionals. Main findings on effectivity, efficacy and implementation will be disseminated via peer-reviewed journals and via (inter)national conferences. Trial registration number: NCT06593704
- Open Access
- 9 February 2026
- Published by Oxford University Press (OUP) in European Journal of Preventive Cardiology
Improving 10-year cardiovascular risk prediction in patients with established cardiovascular disease: flexible addition of risk predictors on top of the SMART2 risk score
Aims: Guidelines recommend using the SMART2 model, estimating the risk of recurrent cardiovascular (CV) events, to support treatment decisions in patients with established atherosclerotic CV disease (ASCVD). They further outline that adding biomarkers, comorbidities, anthropometric, and social factors may improve these predictions. This study aims to investigate the added predictive value of guideline-outlined factors including biomarkers, comorbidities, anthropometric, and social factors on top of the SMART2 model using an approach enabling their use as add-on predictors. Methods and results: Patients aged 40–80 with ASCVD were included from 11 cohorts (n = 179 382 with 25 789 recurrent CV events). Additional factors included biomarkers [troponin I, N-terminal pro-B-type natriuretic peptide (NT-proBNP), albuminuria], comorbidities (heart failure, atrial fibrillation, coronary multivessel disease), anthropometric measurements [body mass index (BMI), waist and hip circumference], social (employment, education), and other factors (former smoking, parental CV history). Cross-cohort availability of these factors ranged from two cohorts for albuminuria to all cohorts for BMI. These factors were assessed as add-on predictors to the SMART2 model using Fine–Gray models with SMART2 coefficients as offset with recurrent CV events as the primary outcome (non-fatal myocardial infarction or stroke, or CV death). Added predictive value was assessed through cohort cross-validation by change (Δ) in C-statistic, calibration, and net benefit through decision curve analysis. Subdistribution hazard ratios for additional factors ranged from 0.77 (95% confidence interval 0.75–0.80) for employment status to 1.69 (1.63–1.76) for heart failure history. ΔC-statistic was largest for NT-proBNP [0.0127 (0.0060–0.0193)] and troponin I [0.0100 (0.0020–0.0181)], with statistically significant but smaller ΔC-statistics for employment, heart failure, and atrial fibrillation. Calibration was adequate before and after integration of additional factors. Decision curve analysis demonstrated added net benefit beyond SMART2 for NT-proBNP, heart failure history, atrial fibrillation, albuminuria, current employment, coronary multivessel disease, and education level across clinically relevant thresholds up to 40% predicted risk. Conclusion: The flexible add-on of guideline-outlined factors on top of SMART2 enables more personalized and improved estimation of recurrent CV event risk in patients with established ASCVD.
- 9 February 2026
- Published by Oxford University Press (OUP) in European Journal of Preventive Cardiology
Open AccessImproving 10-year cardiovascular risk prediction in patients with established cardiovascular disease: flexible addition of risk predictors on top of the SMART2 risk score
Aims: Guidelines recommend using the SMART2 model, estimating the risk of recurrent cardiovascular (CV) events, to support treatment decisions in patients with established atherosclerotic CV disease (ASCVD). They further outline that adding biomarkers, comorbidities, anthropometric, and social factors may improve these predictions. This study aims to investigate the added predictive value of guideline-outlined factors including biomarkers, comorbidities, anthropometric, and social factors on top of the SMART2 model using an approach enabling their use as add-on predictors. Methods and results: Patients aged 40–80 with ASCVD were included from 11 cohorts (n = 179 382 with 25 789 recurrent CV events). Additional factors included biomarkers [troponin I, N-terminal pro-B-type natriuretic peptide (NT-proBNP), albuminuria], comorbidities (heart failure, atrial fibrillation, coronary multivessel disease), anthropometric measurements [body mass index (BMI), waist and hip circumference], social (employment, education), and other factors (former smoking, parental CV history). Cross-cohort availability of these factors ranged from two cohorts for albuminuria to all cohorts for BMI. These factors were assessed as add-on predictors to the SMART2 model using Fine–Gray models with SMART2 coefficients as offset with recurrent CV events as the primary outcome (non-fatal myocardial infarction or stroke, or CV death). Added predictive value was assessed through cohort cross-validation by change (Δ) in C-statistic, calibration, and net benefit through decision curve analysis. Subdistribution hazard ratios for additional factors ranged from 0.77 (95% confidence interval 0.75–0.80) for employment status to 1.69 (1.63–1.76) for heart failure history. ΔC-statistic was largest for NT-proBNP [0.0127 (0.0060–0.0193)] and troponin I [0.0100 (0.0020–0.0181)], with statistically significant but smaller ΔC-statistics for employment, heart failure, and atrial fibrillation. Calibration was adequate before and after integration of additional factors. Decision curve analysis demonstrated added net benefit beyond SMART2 for NT-proBNP, heart failure history, atrial fibrillation, albuminuria, current employment, coronary multivessel disease, and education level across clinically relevant thresholds up to 40% predicted risk. Conclusion: The flexible add-on of guideline-outlined factors on top of SMART2 enables more personalized and improved estimation of recurrent CV event risk in patients with established ASCVD.
- Open Access
- 1 January 2026
- Published by Sociedade Brasileira de Cardiologia in Arquivos Brasileiros de Cardiologia
- Vol. 123 (9)
Development and External Validation of the SCORE2 Models in Latin America and the Caribbean (SCORE2-LAC) to Estimate 10-Year Cardiovascular Disease Risk
Background and Aims Despite the high burden of cardiovascular disease (CVD) in Latin America and the Caribbean (LAC), risk prediction models adapted for use in LAC populations remain limited. The aim of this study was to recalibrate the Systematic COronary Risk Evaluation 2 (SCORE2) risk models for estimating 10-year CVD risk in individuals without prior CVD or diabetes mellitus in LAC, resulting in the SCORE2 Latin America and the Caribbean (SCORE2-LAC) models. Methods Sex-specific, competing risk-adjusted SCORE2 models were recalibrated to contemporary CVD incidence across four risk regions, defined by country-level age- and sex-standardized CVD mortality rates, using region-specific risk factor distributions. Cardiovascular disease incidence was estimated from CVD mortality data and ratios of the total first-to-fatal CVD events, derived from 40 237 152 individuals (1 261 329 CVD events). External validation included 132 512 individuals without prior CVD or diabetes from 11 cohorts across seven countries (3938 CVD events). Discrimination was assessed using Harrell’s C-index. Results In the external validation datasets, the pooled C-index of SCORE2-LAC was .740 [95% confidence interval (CI) .716–.763], with cohort-specific C-indices ranging from .674 (95% CI .588–.761) to .789 (95% CI .747–.831). Estimated CVD risk varied several-fold across the four LAC risk regions. For a 50-year-old non-smoker with a systolic blood pressure of 140 mmHg, total cholesterol of 213 mg/dL (5.5 mmol/L), and HDL cholesterol of 50 mg/dL (1.3 mmol/L), the predicted risk ranged from 3% in low-risk countries to 10% in very-high-risk countries for women, and from 4% to 10% for men. Conclusions The SCORE2-LAC models provide region-specific contemporary estimates of 10-year CVD risk in apparently healthy individuals, enabling identification of individuals at high CVD risk across LAC. Structured Graphical
- 1 January 2026
- Published by Sociedade Brasileira de Cardiologia in Arquivos Brasileiros de Cardiologia
- Vol. 123 (9)
Open AccessDevelopment and External Validation of the SCORE2 Models in Latin America and the Caribbean (SCORE2-LAC) to Estimate 10-Year Cardiovascular Disease Risk
Background and Aims Despite the high burden of cardiovascular disease (CVD) in Latin America and the Caribbean (LAC), risk prediction models adapted for use in LAC populations remain limited. The aim of this study was to recalibrate the Systematic COronary Risk Evaluation 2 (SCORE2) risk models for estimating 10-year CVD risk in individuals without prior CVD or diabetes mellitus in LAC, resulting in the SCORE2 Latin America and the Caribbean (SCORE2-LAC) models. Methods Sex-specific, competing risk-adjusted SCORE2 models were recalibrated to contemporary CVD incidence across four risk regions, defined by country-level age- and sex-standardized CVD mortality rates, using region-specific risk factor distributions. Cardiovascular disease incidence was estimated from CVD mortality data and ratios of the total first-to-fatal CVD events, derived from 40 237 152 individuals (1 261 329 CVD events). External validation included 132 512 individuals without prior CVD or diabetes from 11 cohorts across seven countries (3938 CVD events). Discrimination was assessed using Harrell’s C-index. Results In the external validation datasets, the pooled C-index of SCORE2-LAC was .740 [95% confidence interval (CI) .716–.763], with cohort-specific C-indices ranging from .674 (95% CI .588–.761) to .789 (95% CI .747–.831). Estimated CVD risk varied several-fold across the four LAC risk regions. For a 50-year-old non-smoker with a systolic blood pressure of 140 mmHg, total cholesterol of 213 mg/dL (5.5 mmol/L), and HDL cholesterol of 50 mg/dL (1.3 mmol/L), the predicted risk ranged from 3% in low-risk countries to 10% in very-high-risk countries for women, and from 4% to 10% for men. Conclusions The SCORE2-LAC models provide region-specific contemporary estimates of 10-year CVD risk in apparently healthy individuals, enabling identification of individuals at high CVD risk across LAC. Structured Graphical
- Open Access
- 1 January 2026
- Published by Sociedade Brasileira de Cardiologia in Arquivos Brasileiros de Cardiologia
- Vol. 123 (9)
Desenvolvimento e Validação Externa dos Modelos SCORE2 na América Latina e no Caribe (SCORE2-LAC) para Estimar o Risco de Doenças Cardiovasculares em 10 Anos
Resumo Fundamento e objetivos Apesar da elevada carga de doença cardiovascular (DCV) na América Latina e no Caribe (ALC), ainda são escassos os modelos de predição de risco adaptados para uso nas populações da ALC. O objetivo deste estudo foi recalibrar os modelos de risco Systematic COronary Risk Evaluation 2 (SCORE2) para estimar o risco de DCV em 10 anos em indivíduos sem DCV prévia ou diabetes melito na ALC, dando origem aos modelos SCORE2 para a América Latina e o Caribe (SCORE2-LAC). Métodos Os modelos SCORE2 específicos por sexo e ajustados para riscos competitivos foram recalibrados de acordo com a incidência atual de DCV em quatro regiões de risco, definidas com base nas taxas nacionais de mortalidade por DCV padronizadas por idade e sexo. Para a recalibração, foram utilizadas distribuições de fatores de risco específicas de cada região. A incidência de DCV foi estimada com base nos dados de mortalidade por DCV e nas razões entre o total de primeiros eventos e os eventos fatais de DCV, obtidas de 40 237 152 indivíduos (1 261 329 eventos de DCV). A validação externa incluiu 132 512 indivíduos sem DCV prévia ou diabetes provenientes de 11 coortes de sete países (3938 eventos de DCV). A discriminação foi avaliada por meio do índice C de Harrell. Resultados Nos conjuntos de dados de validação externa, o índice C combinado do SCORE2-LAC foi de 0,740 (intervalo de confiança de 95% [IC 95%]: 0,716-0,763), com índices C específicos de cada coorte variando de 0,674 (IC 95%: 0,588-0,761) a 0,789 (IC 95%: 0,747-0,831). O risco estimado de DCV variou substancialmente entre as quatro regiões de risco da ALC. Para uma pessoa de 50 anos, não fumante, com pressão arterial sistólica de 140 mmHg, colesterol total de 213 mg/dL (5,5 mmol/L) e colesterol da lipoproteína de alta densidade de 50 mg/dL (1,3 mmol/L), o risco previsto variou de 3% nos países de baixo risco a 10% nos países de risco muito alto entre as mulheres e de 4% a 10% entre os homens. Conclusões Os modelos SCORE2-LAC fornecem estimativas atuais e específicas por região do risco de DCV em 10 anos em indivíduos aparentemente saudáveis, permitindo identificar aqueles com alto risco de DCV em toda a ALC. Resumo Gráfico Estruturado.
- 1 January 2026
- Published by Sociedade Brasileira de Cardiologia in Arquivos Brasileiros de Cardiologia
- Vol. 123 (9)
Open AccessDesenvolvimento e Validação Externa dos Modelos SCORE2 na América Latina e no Caribe (SCORE2-LAC) para Estimar o Risco de Doenças Cardiovasculares em 10 Anos
Resumo Fundamento e objetivos Apesar da elevada carga de doença cardiovascular (DCV) na América Latina e no Caribe (ALC), ainda são escassos os modelos de predição de risco adaptados para uso nas populações da ALC. O objetivo deste estudo foi recalibrar os modelos de risco Systematic COronary Risk Evaluation 2 (SCORE2) para estimar o risco de DCV em 10 anos em indivíduos sem DCV prévia ou diabetes melito na ALC, dando origem aos modelos SCORE2 para a América Latina e o Caribe (SCORE2-LAC). Métodos Os modelos SCORE2 específicos por sexo e ajustados para riscos competitivos foram recalibrados de acordo com a incidência atual de DCV em quatro regiões de risco, definidas com base nas taxas nacionais de mortalidade por DCV padronizadas por idade e sexo. Para a recalibração, foram utilizadas distribuições de fatores de risco específicas de cada região. A incidência de DCV foi estimada com base nos dados de mortalidade por DCV e nas razões entre o total de primeiros eventos e os eventos fatais de DCV, obtidas de 40 237 152 indivíduos (1 261 329 eventos de DCV). A validação externa incluiu 132 512 indivíduos sem DCV prévia ou diabetes provenientes de 11 coortes de sete países (3938 eventos de DCV). A discriminação foi avaliada por meio do índice C de Harrell. Resultados Nos conjuntos de dados de validação externa, o índice C combinado do SCORE2-LAC foi de 0,740 (intervalo de confiança de 95% [IC 95%]: 0,716-0,763), com índices C específicos de cada coorte variando de 0,674 (IC 95%: 0,588-0,761) a 0,789 (IC 95%: 0,747-0,831). O risco estimado de DCV variou substancialmente entre as quatro regiões de risco da ALC. Para uma pessoa de 50 anos, não fumante, com pressão arterial sistólica de 140 mmHg, colesterol total de 213 mg/dL (5,5 mmol/L) e colesterol da lipoproteína de alta densidade de 50 mg/dL (1,3 mmol/L), o risco previsto variou de 3% nos países de baixo risco a 10% nos países de risco muito alto entre as mulheres e de 4% a 10% entre os homens. Conclusões Os modelos SCORE2-LAC fornecem estimativas atuais e específicas por região do risco de DCV em 10 anos em indivíduos aparentemente saudáveis, permitindo identificar aqueles com alto risco de DCV em toda a ALC. Resumo Gráfico Estruturado.